VE-821

• Background:

  VE-821 is a potent and selective ATP-competitive ATR (Ataxia-telangiectasia and Rad3-related protein) inhibitor, Ki=13 nM.1 Increases the sensitivity of pancreatic2 and ovarian3 cancer cells to radiation and chemotherapy. Increased replication stress induced by PARP inhibitors or chemotherapeutic agents increases sensitivity to VE-821 in neuroblastoma cells.4 Enhances the cytotoxicity of DNA damaging agents.5

• Conjugation:

  Unconjugated

• Buffer:

  Beige solid

• Storage Conditions:

  -20°C